- Home
- CLSD
as 02-21-2025 4:00pm EST
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | ALPHARETTA |
| Market Cap: | 81.2M | IPO Year: | 2016 |
| Target Price: | $5.33 | AVG Volume (30 days): | 206.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.80 - $2.12 | Next Earning Date: | 03-11-2025 |
| Revenue: | $7,703,000 | Revenue Growth: | 248.39% |
| Revenue Growth (this year): | -80.71% | Revenue Growth (next year): | 91.87% |
Latest Clearside Biomedical Inc. News
CLSD Breaking Stock News: Dive into CLSD Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
GlobeNewswire
12 days ago
Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting
GlobeNewswire
18 days ago
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
GlobeNewswire
25 days ago
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
MT Newswires
a month ago
Sector Update: Health Care Stocks Softer Late Afternoon
MT Newswires
a month ago
Clearside's Partner Receives NDA Approvals for Uveitic Macular Edema Treatment in Australia, Singapore
GlobeNewswire
a month ago
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
TipRanks
2 months ago
Clearside announces publication of insights on drug development, regulation
Compare CLSD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLSD Clearside Biomedical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.